{"keywords": [{"value": "Pain-Relieving Drugs", "rank": "1", "is_major": "Y", "name": "subject"}, {"value": "Ostroff, Stephen", "rank": "11", "is_major": "N", "name": "persons"}, {"value": "OxyContin (Drug)", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "Drug Abuse and Traffic", "rank": "3", "is_major": "Y", "name": "subject"}, {"value": "Food and Drug Administration", "rank": "4", "is_major": "Y", "name": "organizations"}, {"value": "Children and Childhood", "rank": "5", "is_major": "N", "name": "subject"}, {"value": "Clinton, Hillary Rodham", "rank": "6", "is_major": "N", "name": "persons"}, {"value": "Cancer", "rank": "7", "is_major": "N", "name": "subject"}, {"value": "American Academy of Pediatrics", "rank": "8", "is_major": "N", "name": "organizations"}, {"value": "Purdue Pharma", "rank": "9", "is_major": "N", "name": "organizations"}, {"value": "Physicians for Responsible Opioid Prescribing", "rank": "10", "is_major": "N", "name": "organizations"}], "headline": {"print_headline": "F.D.A. Approval of OxyContin Use for Children Continues to Draw Scrutiny", "main": "F.D.A. Approval of OxyContin Use for Children Continues to Draw Scrutiny"}, "byline": {"original": "By CATHERINE SAINT LOUIS", "person": [{"middlename": "Saint", "organization": "", "lastname": "LOUIS", "role": "reported", "firstname": "Catherine", "rank": 1}]}, "web_url": "http://www.nytimes.com/2015/10/09/health/fda-approval-of-oxycontin-for-children-continues-to-draw-scrutiny.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "5616dd2d38f0d8690d4b9fe2", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-thumbWide.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-thumbStandard-v2.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/09/science/09OPIOIDS5/09OPIOIDS5-thumbStandard-v2.jpg"}], "pub_date": "2015-10-09T00:00:00Z", "print_page": "20", "section_name": "Health", "word_count": "1110", "blog": [], "news_desk": "National", "snippet": "Many public officials are concerned that the approval will change the way the drug is marketed and used, though the agency says it will lead to better information for doctors.", "document_type": "article", "abstract": "Food and Drug Administration's August decision to approve painkiller OxyContin for use in some children continues to face criticism from politicians, including Hillary Rodham Clinton; some doctors say drug is necessary for some children, although they acknowledge concerns about painkiller addiction are warranted; advocates say new labeling offers important information like dosage recommendations for children.", "lead_paragraph": "Many public officials are concerned that the approval will change the way the drug is marketed and used, though the agency says it will lead to better information for doctors."}